Acromegaly is a rare endocrine disease resulting from a growth hormone (GH)-secreting pituitary adenoma; it has an estimated prevalence of around 60 per million and an annual incidence of 3 or 4 per million. 1, 2 Untreated acromegaly is associated with reduced life expectancy and long-term complications, including cardiometabolic pathology. 3 Indeed, patients with acromegaly have an increased cardiovascular (CV) risk when compared with healthy populations, due to higher prevalence of insulin resistance, type 2 diabetes, dyslipidemia, and hypertension 4 ; however, it seems that these factors by themselves do not lead to a higher rate of CV events. 5 Although epidemiological studies have reported that CV and cerebrovascular events are the main cause of death in patients with acromegaly, 6-8 data on a potential increased prevalence of coronary heart disease (CHD) in these subjects are conflicting. [9] [10] [11] [12] Therefore, despite an unfavorable CV risk profile, it is still unclear whether, and to what extent, patients with acromegaly are at risk of CHD.
The specific CV abnormalities in patients with acromegaly include hypertension 13 and cardiomyopathy (mainly left ventricular hypertrophy and diastolic dysfunction 14 ) that can lead to an increased risk for arrhythmia, valvular disease, 15 and, in a minority of patients, heart failure. 16 The underlying pathophysiological mechanisms are probably indirectly related to hypertension and other established and emerging risk factors but also to a direct anabolic effect of GH on the heart. The latter mechanism is further substantiated by the fact that by medically reducing GH secretion, some of the cardiac abnormalities improve. 17, 18 Novel CV risk factors are relevant if they allow better prediction of vascular events 19 ; in this context, potential alterations in markers of endothelial or cardiac dysfunction, in hemostatic parameters, as well as in atherogenic lipoproteins have been investigated. It has been shown that patients with active acromegaly may have increased levels of plasma markers of endothelial dysfunction, such as endothelin 1. 20 In contrast, concentrations of homocysteine are similar. 20, 21 Other authors have assessed potential alterations in hemostatic parameters, and there are reports of higher concentrations of fibrinogen, tissue plasminogen activator and of its inhibitor I, with decreased protein S and plasma tissue factor pathway inhibitor levels 22 ; overall, this may represent a potential hypercoagulable and hypofibrinolytic state, which might increase the risk of atherosclerotic and atherothrombotic complications.
Potential alterations in atherogenic lipoproteins have also been investigated. Increasing evidence suggests that the ''quality'' as well as the ''quantity'' of plasma lipids and lipoproteins influences CV risk as reflected in the proatherogenic alterations that give rise to elevated levels of small, dense low-density lipoproteins (LDL). 23, 24 A Consensus Statement of a European panel of experts highlighted the pathophysiology, atherogenicity, and clinical significance of these LDL particles. 25, 26 Small dense LDL is increased in acromegaly, [27] [28] [29] and decreasing GH levels in these patients may improve the distribution of LDL subclasses. 29 Patients with acromegaly have also been shown to have increased levels of oxidized LDL, 30 a marker of atherosclerotic plaque formation. 31 Plasma levels of lipoprotein (a), an independent predictor of CHD and CV events (eg, myocardial infarction and stroke), 32, 33 are also increased in patients with active acromegaly, 21 while concentrations of lipoprotein-associated phospholipase A(2), another proatherogenic lipoprotein, 34 seem unchanged. 35 Is the increase in markers of CV risk directly linked to an increased risk of symptomatic atherosclerosis in individuals with acromegaly? This clinically important question remains unanswered. It should be noted, however, that additional insights have been provided by studies investigating the prevalence of subclinical atherosclerosis in patients with acromegaly. For example, ultrasound measurement of carotid intima-media thickness (IMT), a useful marker of early atherosclerosis, is increased in patients with acromegaly [36] [37] [38] ; however, this is not a consistent finding. 39 Boysan et al in the present issue of Angiology 40 suggest that premature atherosclerosis in patients with acromegaly may be a consequence of insulin resistance and direct vascular effects of GH and/or insulin-like growth factor 1 (IGF-1). They 40 highlight that premature atherosclerosis in patients with acromegaly may be a consequence of insulin resistance and direct vascular effects of GH and/or IGF-1. The investigators studied premature atherosclerosis by carotid Doppler ultrasonography in patients with active acromegaly before and after treatment with long-acting somatostatin analogue for 2 years. They assessed a number of clinical and biochemical parameters, including those related to obesity, hypertension, dyslipidemia, and estimated insulin resistance by the homeostasis model of assessment (HOMA-IR). Although there was no significant change in most of the established CV risk factors at the end of the study period, carotid IMT was reduced in the treatment group. Of interest, carotid IMT correlated with HOMA-IR, IGF-1, and the area under the curve of GH. The main limitation of this study is the lack of a detailed analysis on the role of measured risk factors on carotid IMT. In addition, the authors did not assess novel risk factors of interest in acromegaly. The results of the study raise intriguing questions and are consistent with previous observations that the early atherosclerotic process in acromegaly may be attributable not only to the high prevalence of CV risk factors but also to abnormal GH secretion itself. 36 In conclusion, acromegaly is associated with several abnormalities of the cardiac and vascular system. Patients with acromegaly have an increased CV risk when compared with healthy populations, due to a higher prevalence of established and emerging risk factors. In addition, there are direct effects of GH and IGF-1 on target tissues of the CV system. 41 It remains, therefore, a scientific challenge to causally link the increased CV risk to ''risk factor mediated'' or ''direct effect'' of GH. It is likely that both pathophysiological mechanisms play a role. If true, they provide another important justification for a concerted effort to manage acromegaly with the aim of normalizing GH and IGF-1 levels.
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